Atgen Co. Ltd. | Cash Flow

Fiscal year is January-December. All values KRW Thousands.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
3,180,579.20
5,840,187.20
5,373,875.50
4,837,497.20
16,631,716.40
Depreciation, Depletion & Amortization
410,262.50
288,058.20
373,042.90
587,607.50
717,604.70
Other Funds
1,246,567.10
938,604.30
749,764.00
2,565,065.90
1,808,993.30
Funds from Operations
1,523,749.60
4,613,524.70
5,750,596.60
6,814,955.60
14,105,118.40
Changes in Working Capital
1,012,823.20
449,070.80
2,202,641.70
3,425,953.80
1,159,724.30
Net Operating Cash Flow
2,536,572.90
5,062,595.50
7,953,238.30
10,240,909.40
15,264,842.70
Capital Expenditures
722,910.80
426,653.50
542,659.40
1,946,998.50
2,415,733.50
Sale of Fixed Assets & Businesses
20,097.10
-
-
440,000.00
2,272.70
Purchase/Sale of Investments
131,426.40
40,896.00
2,815,963.20
17,075,488.20
3,555,609.30
Net Investing Cash Flow
834,240.10
467,549.50
3,358,622.60
19,750,966.50
6,026,979.70
Issuance/Reduction of Debt, Net
2,634,100.50
3,473,420.50
12,899,500.00
29,736,000.00
-
Net Financing Cash Flow
3,652,513.90
8,815,795.50
30,922,761.80
39,805,004.30
960,000.00
Net Change in Cash
279,844.00
3,285,224.40
19,615,566.60
9,760,841.20
20,406,607.00
Free Cash Flow
3,241,525.90
5,488,050.60
8,453,891.30
12,166,097.10
16,635,262.60
Other Sources
-
-
-
639,179.00
91,661.00
Change in Capital Stock
1,018,413.30
5,342,375.00
18,023,261.80
10,069,004.30
960,000.00
Exchange Rate Effect
1,856.90
426.10
4,665.70
52,287.20
74,784.60
Other Uses
-
-
-
1,807,658.80
149,570.70

About Atgen Co.

View Profile
Address
1st & 6th Floor, Health Care Park
Seongnam-si GY 13605
Korea, Republic Of
Employees -
Website http://www.nkvue.com
Updated 09/14/2018
ATGen Co., Ltd. engages in the development, manufacture, and sale of recombinant proteins and monoclonal antibodies. Its products include NK cells under NK Vue brand, recombinant proteins, and monoclonal antibodies. The company was founded on January 14, 2002 and is headquartered at Seongnam-si, South Korea.